JP2022520107A5 - - Google Patents

Info

Publication number
JP2022520107A5
JP2022520107A5 JP2021547420A JP2021547420A JP2022520107A5 JP 2022520107 A5 JP2022520107 A5 JP 2022520107A5 JP 2021547420 A JP2021547420 A JP 2021547420A JP 2021547420 A JP2021547420 A JP 2021547420A JP 2022520107 A5 JP2022520107 A5 JP 2022520107A5
Authority
JP
Japan
Prior art keywords
composition
antibody
use according
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021547420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018113 external-priority patent/WO2020168079A1/en
Publication of JP2022520107A publication Critical patent/JP2022520107A/ja
Publication of JP2022520107A5 publication Critical patent/JP2022520107A5/ja
Priority to JP2025051765A priority Critical patent/JP2025092553A/ja
Withdrawn legal-status Critical Current

Links

JP2021547420A 2019-02-14 2020-02-13 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 Withdrawn JP2022520107A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025051765A JP2025092553A (ja) 2019-02-14 2025-03-26 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962805350P 2019-02-14 2019-02-14
US62/805,350 2019-02-14
US201962814935P 2019-03-07 2019-03-07
US62/814,935 2019-03-07
PCT/US2020/018113 WO2020168079A1 (en) 2019-02-14 2020-02-13 Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025051765A Division JP2025092553A (ja) 2019-02-14 2025-03-26 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与

Publications (2)

Publication Number Publication Date
JP2022520107A JP2022520107A (ja) 2022-03-28
JP2022520107A5 true JP2022520107A5 (enExample) 2023-02-20

Family

ID=69954108

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547420A Withdrawn JP2022520107A (ja) 2019-02-14 2020-02-13 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与
JP2025051765A Pending JP2025092553A (ja) 2019-02-14 2025-03-26 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025051765A Pending JP2025092553A (ja) 2019-02-14 2025-03-26 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与

Country Status (9)

Country Link
US (2) US20200331993A1 (enExample)
EP (1) EP3924380A1 (enExample)
JP (2) JP2022520107A (enExample)
KR (2) KR20260046520A (enExample)
CN (2) CN113614106A (enExample)
AU (1) AU2020223298A1 (enExample)
CA (1) CA3130300A1 (enExample)
MX (1) MX2021009789A (enExample)
WO (1) WO2020168079A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
DE102021120603A1 (de) * 2020-08-24 2022-02-24 Nvidia Corporation Techniken des maschinellen lernens zur sauerstofftherapievorhersage unter verwendung von medizinischen bildgebungsdaten und klinischen metadaten
EP4281472A1 (en) * 2021-01-22 2023-11-29 Alexion Pharmaceuticals, Inc. Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
US20250154232A1 (en) * 2021-07-14 2025-05-15 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CA3024618A1 (en) * 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CN118512588A (zh) * 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用

Similar Documents

Publication Publication Date Title
JP2022520107A5 (enExample)
US11453716B2 (en) Single domain serum albumin binding protein
JP2021526534A5 (enExample)
JP2018535948A5 (enExample)
RU2015114923A (ru) СПОСОБЫ ЛЕЧЕНИЯ IL-1β-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ
WO2020097099A1 (en) Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
JP2020536097A5 (enExample)
US10954292B2 (en) Anti-PACAP antibody
CN111108117A (zh) 胰高血糖素样肽1受体激动剂及其用途
JP2021525718A5 (enExample)
JP2020521745A (ja) 治療用抗ｃｄ４０リガンド抗体
WO2021044287A1 (en) Treatment of liver disease or disorder comprising actrii receptor antagonists
CN111886252A (zh) 促进胰岛细胞生长的方法
JP2019519584A5 (enExample)
US20120308564A1 (en) Treatment of a metabolic disorder
JP2023537078A5 (enExample)
JP2023542879A5 (enExample)
JP2018533588A (ja) 治療パラダイム
TW202235435A (zh) 抗cd38抗體及其用途
JP2023506779A5 (enExample)
JP2024526742A5 (enExample)
JP7217287B2 (ja) アミロイド症の処置および予防
US20250270274A1 (en) Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity
US20240043545A1 (en) Methods and compositions for treatment of thyroid eye disease
EA044759B1 (ru) Лечение и профилактика амилоидоза